News
Why Israel? Did you know Tel Aviv has the highest number of startups per capita in the world? (It also boasts the most GDP investment…
Read More
The OIS Index of ophthalmic stocks gained 5.2% in October, posting its first month of positive performance since June. The index lagged the biotech sector…
Read More
It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as…
Read More
What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The…
Read More
OIS Contributors An eye drop with the potential to fix, albeit temporarily, presbyopia. An artificial endothelial cornea, ready for trial. A neurostimulation device for dry…
Read More
CHICAGO—The first gene therapy approved in the United States happened to be for an inherited eye disease, with an agent that is administered subretinally. But…
Read More
The OIS Index of ophthalmic stocks posted a miserable Q3 performance, led by the biopharmaceutical stocks in the index. The OIS Index (-12.0%) underperformed the…
Read More
CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms…
Read More
SAN FRANCISCO — Winners of a “Shark Tank” style challenge in cataract/refractive and retina and specialty showcase sessions targeting four themes, including gene and cell…
Read More
Innovation Case Study: LensGen Focusing on a Complete Presbyopia Correcting IOL for Declining Vision
LensGen CEO Ramgopal Rao says the company has been built around a laser focus on customers’ needs and wants. That led LensGen to identify a…
Read More
As noted in a previous installment, innovators in the retina space sometimes utilize ex-US partnerships for financing the expensive process of taking drugs and devices…
Read More
CHICAGO – As innovation in the retina space has grown over the past quarter century, so has the need for capital to finance those activities.…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")